PURPOSE: To compare the effiacy of combination of Fluticasone and Salmeterol,Fluticasone, Salmeterol and montelukast; Fluticasone, Salmeterol and levocetrizine in moderate persist asthma.
METHODS: . The patients were randomized into three groups of forty each. Group A (Fluticasone and Salmeterol), group B (Fluticasone, Salmeterol and montelukast), group C (Fluticasone, Salmeterol and levocetrizine) patients were called regularly after every two weeks for assessment of their symptoms with peak expiratory flow measurements till twelve weeks and the benefits of added medications were finally assessed.
RESULTS: Mean increase in peak expiratory flow rates (PEFR) after twelve weeks in group A, group B and group C were 225.25±40.02, 226.50±40.22 and 229.25±44.45 respectively.
CONCLUSION: The PEFR value that is an indicator of airway obstruction showed no significant comparative difference in all the three groups, though there was a significant difference within each group at different time intervals.
CLINICAL IMPLICATIONS: Thus there is no justification of increasing the number of drugs in the treatment protocol of patients in usual practice as it adds to the avoidable expenditure and increased side effects. In addition to this, there is no steroid sparing effect with the use of these drugs.
DISCLOSURE: Sandeep Gupta, No Financial Disclosure Information; No Product/Research Disclosure Information